Physician profile
Nader A Botros
NPI 1851498885
$5,624.32
in general payments reported to CMS, 2019-2025
37 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $793 · 2021: $1,077 · 2022: $1,302 · 2023: $600 · 2024: $438 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,226.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $818.09 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.92 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| United Therapeutics Corporation | $356.56 | 2019-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $292.54 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $244.33 | 2019-2025 | Xywav, Epidiolex |
| Actelion Pharmaceuticals US, INC. | $215.20 | 2020-2025 | Opsumit |
| Genzyme Corporation | $203.16 | 2019-2025 | |
| Insmed, INC. | $161.49 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $151.88 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $146.46 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $124.75 | 2019-2024 | Keytruda |
| Genentech USA, INC. | $109.09 | 2019-2022 | |
| Harmony Biosciences LLC | $101.78 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $88.44 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.57 | 2021-2022 | |
| Amgen INC. | $80.86 | 2022-2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $79.56 | 2022 | |
| Portola Pharmaceuticals, LLC | $78.68 | 2019-2020 | |
| Verona Pharma, INC. | $55.86 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $47.39 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.30 | 2021 | |
| Axsome Therapeutics, INC. | $32.31 | 2022 | |
| Baxter Healthcare | $28.13 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $26.09 | 2020 | |
| Fisher & Paykel Healthcare INC | $22.43 | 2024 | Fisher & Paykel Healthcare |
| Bayer Healthcare Pharmaceuticals INC. | $19.93 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.56 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $18.78 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.14 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.03 | 2023 | Horizant |
| Pfizer INC. | $15.50 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.68 | 2021 | |
| Grifols USA, LLC | $14.59 | 2022 | |
| Boston Scientific Corporation | $14.51 | 2020 | |
| Covis Pharma Gmbh | $13.64 | 2022 | |
| Resmed Corp | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.